Form 4 for NVAX NOVAVAX INC

Accepted 2022-12-16 00:00:00 ET · period of report 2022-12-14 · accession 0001209191-22-061707 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-12-16	2022-12-14	NVAX	Trizzino John	EVP, CCO, CBO	F - Tax	$17.23	-773	6,922	-10%	-$13.3K
D	2022-12-16	2022-12-14	NVAX	Trizzino John	EVP, CCO, CBO	M - OptEx	—	+1,600	7,695	+26%	—
D	2022-12-16	2022-12-14	NVAX	Trizzino John	EVP, CCO, CBO	M - OptEx	$0.00	-1,600	1,600	-50%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-14	F	D	773	$17.23	6,922	D	—	—	(F4) The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022.
2	Common	Common Stock	2022-12-14	M	A	1,600	—	7,695	D	—	—	(F2) Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
3	Derivative	Restricted Stock Units	2022-12-14	M	D	1,600	$0.00	1,600	D	— · — to —	1,600 Common Stock	(F2) Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. (F5) The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date.